- Home
- LPRO vs CGEM Comparison
LPRO vs CGEM Comparison
Compare LPRO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPRO
- CGEM
- Stock Information
- Founded
- LPRO 2000
- CGEM 2016
- Country
- LPRO United States
- CGEM United States
- Employees
- LPRO N/A
- CGEM N/A
- Industry
- LPRO Finance: Consumer Services
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- LPRO Finance
- CGEM Health Care
- Exchange
- LPRO Nasdaq
- CGEM Nasdaq
- Market Cap
- LPRO 252.9M
- CGEM 482.7M
- IPO Year
- LPRO N/A
- CGEM 2021
- Fundamental
- Price
- LPRO $2.10
- CGEM $6.46
- Analyst Decision
- LPRO Buy
- CGEM Strong Buy
- Analyst Count
- LPRO 6
- CGEM 8
- Target Price
- LPRO $3.00
- CGEM $27.25
- AVG Volume (30 Days)
- LPRO 518.0K
- CGEM 539.1K
- Earning Date
- LPRO 11-06-2025
- CGEM 11-06-2025
- Dividend Yield
- LPRO N/A
- CGEM N/A
- EPS Growth
- LPRO N/A
- CGEM N/A
- EPS
- LPRO N/A
- CGEM N/A
- Revenue
- LPRO $16,254,999.00
- CGEM N/A
- Revenue This Year
- LPRO $311.24
- CGEM N/A
- Revenue Next Year
- LPRO $13.17
- CGEM N/A
- P/E Ratio
- LPRO N/A
- CGEM N/A
- Revenue Growth
- LPRO N/A
- CGEM N/A
- 52 Week Low
- LPRO $0.70
- CGEM $6.32
- 52 Week High
- LPRO $6.92
- CGEM $18.62
- Technical
- Relative Strength Index (RSI)
- LPRO 45.18
- CGEM 48.92
- Support Level
- LPRO $2.09
- CGEM N/A
- Resistance Level
- LPRO $2.34
- CGEM $6.76
- Average True Range (ATR)
- LPRO 0.12
- CGEM 0.39
- MACD
- LPRO -0.00
- CGEM -0.33
- Stochastic Oscillator
- LPRO 25.76
- CGEM 79.59
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.